Back

The effectiveness of tafamidis to stabilize the disease progression of transthyretin amyloidosis in hereditary and wild-type subtypes

29 August 2026 (14:15 - 14:45)
Organised by: Logo
Congress Presentation Part of: Heart failure at the crossroads: tafamidis, ageing, and vaccination Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Mounira Kharoubi

University Hospital Henri Mondor, Creteil (France)

4 More presentations in this session

Presentation thumbnail
Cardiohepatic collision: escalating mortality, stark disparities, and pandemic surge in chronic liver disease and heart failure – a 25-year US analysis
Doctor V. Purewal (Scottsdale, US)
Abstract Slides
Presentation thumbnail
Diverging trends in total and heart failure-specific disease burden by age: A 20-year nationwide study in Denmark
Miss C. Garred (Herlev, DK)
Abstract Slides
Presentation thumbnail
Joint association of left bundle branch block and cardiomyopathy with incident heart failure: a prospective UK Biobank cohort study
Doctor S. Cheng (Beijing, CN)
Abstract Slides
Presentation thumbnail
Frailty across the lifespan in heart failure: age-modified drivers and prognostic implications
Doctor V. Copeland (Ramat Gan, IL)
Abstract Slides

Access the full session

Session thumbnail
Heart failure at the crossroads: tafamidis, ageing, and vaccination

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Atrial fibrillation in wild type transthyretin cardiac amyloidosis: prevalence, incidence and outcomes
23 May 2022
thumbnail
Congress Session
Decoding hATTR: exploring disease progression and management strategies
12 May 2024
thumbnail
Congress Presentation
Beta-blocker exposure and long-term survival in patients with transthyretin amyloid cardiomyopathy.
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources